Stockwatch: The Complex Biologics Market Is…Complex
Lovenox And Copaxone Generic Challenges Foreshadow Biosimilar Market Inhibition
The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.